simplyStocks
Explore all companies →

Hims & Hers Health, Inc.

HIMS · NYSEHealthcare
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
Inputs &supplyAPIs, bioprocess, compone…ManufacturingDrug substance, fill-fini…ProductsMedicines, therapies, dev…Payers &distributionWholesalers, PBMs, health…Providers &patientsHospitals, surgeons, pati…APIAPI & ingredient suppliersPEPPeptide facility (ex-CS Bio)NVONovo NordiskRXAffiliated & 503B pharmaciesMSRMedisourceRxAPOApostropheOP&FOhio pharmacy & fulfillmentHHims & HersZAVZAVATDOCTeladoc HealthLFMDLifeMDDRLicensed provider networkTRYTrybe LabsAMZNAmazon (Pharmacy / One Medical)YOUSubscribersWHLWholesale & retail partners
Company details
Market cap
~$7.6B
P/E ratio
~60×
Div yield
0%
EPS (TTM)
~$0.55
Profit margin
5%
Rev. growth
+59%
Revenue
$2.35B
Free cash flow
$57M
In plain English
Hims & Hers is a direct-to-consumer telehealth platform: you fill out a questionnaire online, a licensed provider prescribes, and an affiliated pharmacy ships the medicine to your door on a subscription. It sells care for hair loss, sexual health, skin, mental health and — its fastest-growing line — weight loss. Revenue hit $2.35B in 2025 (+59%), with 2.5M subscribers, but ~98% of sales run through its own website and it leans heavily on compounded (copycat) versions of blockbuster drugs — a model under sharp regulatory scrutiny.
In simple terms
What Hims & Hers Health, Inc. really sells
Hims & Hers is a direct-to-consumer telehealth platform: you fill out a questionnaire online, a licensed provider prescribes, and an affiliated pharmacy ships the medicine to your door on a subscription. It sells care for hair loss, sexual health, skin, mental health and — its fastest-growing line — weight loss. Revenue hit $2.35B in 2025 (+59%), with 2.5M subscribers, but ~98% of sales run through its own website and it leans heavily on compounded (copycat) versions of blockbuster drugs — a model under sharp regulatory scrutiny.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
High
SteadierMore speculative
Why this rating?